Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 27 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerActive, not recruitingNCT03473743Phase 1/2Results posted
• Phase 1A Safety Trial of Inhaled PK10571 (GB002)CompletedNCT03473236Phase 1Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerCompletedNCT03472365Phase 2Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedNCT03468855Phase 2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Phase 3Results posted
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
• Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesCompletedNCT03463525Phase 1Results posted
• A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03462719Phase 3Results posted
• ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate CancerCompletedNCT03456804Phase 2Results posted
• A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingNCT03456076Phase 3Results posted
• G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedNCT03455829Phase 1/2Results posted
• ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerTerminatedNCT03445000Phase 2Results posted
• Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerCompletedNCT03439891Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03435081Phase 3Results posted
• A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsCompletedNCT03434418Phase 2Results posted
• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results posted
• Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryActive, not recruitingNCT03433469Phase 2Results posted
• A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically AdvisableCompletedNCT03428100Phase 3Results posted
• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.CompletedNCT03427866Phase 2Results posted
• Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
• A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsCompletedNCT03420742Phase 1Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionCompletedNCT03417778Phase 1Results posted
• Osimertinib for NSCLC With EGFR Exon 20 Insertion MutationCompletedNCT03414814Phase 2Results posted
• Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03410693Phase 2/3Results posted
• Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03410108Phase 2Results posted
• An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusTerminatedNCT03407482Phase 2Results posted
• Regorafenib and Nivolumab Simultaneous Combination TherapyCompletedNCT03406871Phase 1Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)CompletedNCT03395210Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedNCT03395184Phase 2Results posted
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingNCT03390504Phase 3Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 3Results posted
• Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical CarcinomaCompletedNCT03370718Phase 2Results posted
• A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataTerminatedNCT03354637Phase 2Results posted
• Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer TherapiesCompletedNCT03353753Phase 3Results posted
• Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) AlterationsTerminatedNCT03352427Phase 2Results posted
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03349060Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic TherapiesCompletedNCT03345849Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyCompletedNCT03345836Phase 3Results posted
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersTerminatedNCT03345784Phase 1Results posted
• A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast CancerCompletedNCT03344536Phase 1/2Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell CarcinomaCompletedNCT03339219Phase 2Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic DermatitisCompletedNCT03334435Phase 3Results posted
• Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334422Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic DermatitisCompletedNCT03334396Phase 3Results posted
• Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal CancersCompletedNCT03332498Phase 1/2Results posted
• Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)CompletedNCT03332173Phase 2Results posted
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingNCT03330847Phase 2Results posted
• A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03323151Phase 1/2Results posted
• A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line TherapiesCompletedNCT03321630Phase 2Results posted
• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT03318939Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is ToleratedCompletedNCT03315936Phase 1Results posted
• Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)CompletedNCT03315689Phase 2Results posted
• Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibCompletedNCT03314740Phase 2Results posted
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung FibrosisCompletedNCT03313180Phase 3Results posted
• A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerTerminatedNCT03292133Phase 2Results posted
• Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver MalignanciesCompletedNCT03291379Early Phase 1Results posted
• Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedNCT03291288Phase 1Results posted
• Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted
• A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)CompletedNCT03289533Phase 1Results posted
• Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerTerminatedNCT03289039Phase 2Results posted
• Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With LupusCompletedNCT03288324Phase 1/2Results posted
• LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal CarcinomaTerminatedNCT03287947Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)CompletedNCT03285711Phase 2Results posted
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)CompletedNCT03285490Phase 3Results posted
• A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or ScalpCompletedNCT03285477Phase 3Results posted
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionTerminatedNCT03281304Phase 4Results posted
• Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)CompletedNCT03274076Phase 1/2Results posted
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
• Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell TransplantCompletedNCT03267186Phase 2Results posted
• DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03255083Phase 1Results posted
• AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 AmplificationCompletedNCT03253679Phase 2Results posted
• An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCompletedNCT03252587Phase 2Results posted
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1Results posted
• Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerCompletedNCT03246074Phase 1Results posted
• Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsCompletedNCT03245151Phase 1/2Results posted
• A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With OsimertinibCompletedNCT03239340Phase 2Results posted
• A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)TerminatedNCT03238651Phase 1Results posted
• Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerCompletedNCT03238196Phase 1Results posted
• Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisCompletedNCT03233230Phase 2Results posted
• Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCompletedNCT03230318Phase 2Results posted
• A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedNCT03225716Phase 1Results posted
• Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasActive, not recruitingNCT03220022Phase 1Results posted
• To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal CancerCompletedNCT03215264Phase 1Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaTerminatedNCT03213626Phase 2Results posted
• A Study of Baricitinib in Healthy ParticipantsCompletedNCT03212638Phase 1Results posted
• Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver CancerCompletedNCT03211416Phase 1/2Results posted

← Tyrosine Kinase Inhibitors overview